Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With Obesity Causing Genetic Mutations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 11 May 2016 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 07 Dec 2015 According to CT.gov, expanded access study changed to phase II interventional study.Accordingly,study dates, design-keywords,endpoints, treatment section and patient number have been updated.